Enzo Biochem (NYSE:ENZ) Coverage Initiated by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Enzo Biochem (NYSE:ENZ) in a report released on Friday morning. The firm issued a hold rating on the medical research company’s stock.

Enzo Biochem Trading Down 1.7 %

NYSE:ENZ opened at $1.16 on Friday. Enzo Biochem has a one year low of $0.99 and a one year high of $1.50. The firm’s fifty day moving average price is $1.12 and its two-hundred day moving average price is $1.14.

Institutional Investors Weigh In On Enzo Biochem

Institutional investors and hedge funds have recently bought and sold shares of the company. XTX Topco Ltd lifted its holdings in shares of Enzo Biochem by 94.5% in the second quarter. XTX Topco Ltd now owns 28,262 shares of the medical research company’s stock worth $31,000 after acquiring an additional 13,735 shares during the last quarter. Renaissance Technologies LLC increased its stake in shares of Enzo Biochem by 2.6% in the second quarter. Renaissance Technologies LLC now owns 2,499,546 shares of the medical research company’s stock valued at $2,725,000 after buying an additional 64,417 shares during the period. Finally, Wittenberg Investment Management Inc. acquired a new position in shares of Enzo Biochem in the fourth quarter valued at approximately $95,000. Institutional investors own 36.90% of the company’s stock.

About Enzo Biochem

Enzo Biochem, Inc develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis.